Endocannabinoids and Neurodegenerative Disorders: Parkinson's Disease, Huntington's Chorea, Alzheimer's Disease, and Others (Q38593124)

4 September 2017

Endocannabinoids and Neurodegenerative Disorders: Parkinson's Disease, Huntington's Chorea, Alzheimer's Disease, and Others (English)

1 reference

4 September 2017

0 references

0 references

0 references

1 reference

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26408163%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

author name string

Javier Fernández-Ruiz

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26408163%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

José A Ramos

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26408163%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

publication date

1 January 2015

1 reference

Handbook of experimental pharmacology

4 September 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26408163%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

volume

231

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26408163%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

page(s)

233-259

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26408163%20AND%20SRC:MED&resulttype=core&format=json

Activation of the CB1 cannabinoid receptor protects cultured mouse spinal neurons against excitotoxicity

3 June 2020

cites work

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-20825-1_8

CB1 agonist ACEA protects neurons and reduces the cognitive impairment of AβPP/PS1 mice.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-20825-1_8

CB2 cannabinoid receptor agonist ameliorates Alzheimer-like phenotype in AβPP/PS1 mice.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-20825-1_8

The ongoing pursuit of neuroprotective therapies in Parkinson disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-20825-1_8

Cannabinoid CB2 receptors and fatty acid amide hydrolase are selectively overexpressed in neuritic plaque-associated glia in Alzheimer's disease brains

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-20825-1_8

β-Amyloid exacerbates inflammation in astrocytes lacking fatty acid amide hydrolase through a mechanism involving PPAR-α, PPAR-γ and TRPV1, but not CB₁ or CB₂ receptors

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-20825-1_8

Investigational drugs in Alzheimer's disease: current progress

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-20825-1_8

Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-20825-1_8

Loss of striatal type 1 cannabinoid receptors is a key pathogenic factor in Huntington's disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-20825-1_8

Cannabinoid receptor 2 signaling in peripheral immune cells modulates disease onset and severity in mouse models of Huntington's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-20825-1_8

Cultured rat microglial cells synthesize the endocannabinoid 2-arachidonylglycerol, which increases proliferation via a CB2 receptor-dependent mechanism

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-20825-1_8

Δ⁹-tetrahydrocannabinol (Δ⁹-THC) exerts a direct neuroprotective effect in a human cell culture model of Parkinson's disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-20825-1_8

Natural cannabinoids improve dopamine neurotransmission and tau and amyloid pathology in a mouse model of tauopathy.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-20825-1_8

The neuroprotective effect of cannabidiol in an in vitro model of newborn hypoxic-ischemic brain damage in mice is mediated by CB(2) and adenosine receptors.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-20825-1_8

Human brain capillary endothelium: 2-arachidonoglycerol (endocannabinoid) interacts with endothelin-1

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-20825-1_8

Monoacylglycerol lipase is a therapeutic target for Alzheimer's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-20825-1_8

Δ9-THC-caused synaptic and memory impairments are mediated through COX-2 signaling

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-20825-1_8

A restricted population of CB1 cannabinoid receptors with neuroprotective activity

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-20825-1_8

Activation of cannabinoid CB2 receptor-mediated AMPK/CREB pathway reduces cerebral ischemic injury.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-20825-1_8

Cannabinoid receptor type 1 protects nigrostriatal dopaminergic neurons against MPTP neurotoxicity by inhibiting microglial activation

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-20825-1_8

Epigenetic regulation of fatty acid amide hydrolase in Alzheimer disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-20825-1_8

Nonpsychoactive cannabidiol prevents prion accumulation and protects neurons against prion toxicity.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-20825-1_8

Cannabinoid receptor CB2 is expressed on vascular cells, but not astroglial cells in the post-mortem human Huntington's disease brain.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-20825-1_8

CB₁ receptor activation inhibits neuronal and astrocytic intermediary metabolism in the rat hippocampus

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-20825-1_8

Neuroprotective effect of (-)Delta9-tetrahydrocannabinol and cannabidiol in N-methyl-D-aspartate-induced retinal neurotoxicity: involvement of peroxynitrite

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-20825-1_8

Cannabidiol inhibits inducible nitric oxide synthase protein expression and nitric oxide production in beta-amyloid stimulated PC12 neurons through p38 MAP kinase and NF-kappaB involvement

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-20825-1_8

The marijuana component cannabidiol inhibits beta-amyloid-induced tau protein hyperphosphorylation through Wnt/beta-catenin pathway rescue in PC12 cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-20825-1_8

Cannabidiol in vivo blunts beta-amyloid induced neuroinflammation by suppressing IL-1beta and iNOS expression

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-20825-1_8

Cannabidiol reduces Aβ-induced neuroinflammation and promotes hippocampal neurogenesis through PPARγ involvement

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-20825-1_8

A molecular link between the active component of marijuana and Alzheimer's disease pathology

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-20825-1_8

The influence of cannabinoids on generic traits of neurodegeneration

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-20825-1_8

WIN55212-2 attenuates amyloid-beta-induced neuroinflammation in rats through activation of cannabinoid receptors and PPAR-γ pathway.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-20825-1_8

The endocannabinoid system as a target for the treatment of motor dysfunction

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-20825-1_8

Cannabinoid CB2 receptor: a new target for controlling neural cell survival?

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-20825-1_8

The endocannabinoid system as a target for the treatment of neuronal damage

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-20825-1_8

Cannabidiol for neurodegenerative disorders: important new clinical applications for this phytocannabinoid?

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-20825-1_8

Neuroprotective properties of peroxisome proliferator-activated receptor alpha (PPARα) and its lipid ligands

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-20825-1_8

Modulation of the endocannabinoid system: neuroprotection or neurotoxicity?

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-20825-1_8

Cannabinoid type 2 receptor stimulation attenuates brain edema by reducing cerebral leukocyte infiltration following subarachnoid hemorrhage in rats

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-20825-1_8

Symptom-relieving and neuroprotective effects of the phytocannabinoid Δ⁹-THCV in animal models of Parkinson's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-20825-1_8

Identification of CB₂ receptors in human nigral neurons that degenerate in Parkinson's disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-20825-1_8

Evaluation of the neuroprotective effect of cannabinoids in a rat model of Parkinson's disease: importance of antioxidant and cannabinoid receptor-independent properties.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-20825-1_8

Cannabinoids and Parkinson's disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-20825-1_8

Rationally designed multi-targeted agents against neurodegenerative diseases

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-20825-1_8

The pattern of neurodegeneration in Huntington's disease: a comparative study of cannabinoid, dopamine, adenosine and GABA(A) receptor alterations in the human basal ganglia in Huntington's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-20825-1_8

The constitutive production of the endocannabinoid 2-arachidonoylglycerol participates in oligodendrocyte differentiation.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-20825-1_8

Cannabinoid receptor agonists modulate oligodendrocyte differentiation by activating PI3K/Akt and the mammalian target of rapamycin (mTOR) pathways.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-20825-1_8

The multiplicity of action of cannabinoids: implications for treating neurodegeneration

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-20825-1_8

Experimental parkinsonism alters endocannabinoid degradation: implications for striatal glutamatergic transmission.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-20825-1_8

Neuroprotective effect of cannabidiol, a non-psychoactive component from Cannabis sativa, on beta-amyloid-induced toxicity in PC12 cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-20825-1_8

Cannabidiol: a promising drug for neurodegenerative disorders?

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-20825-1_8

Anandamide protects HT22 cells exposed to hydrogen peroxide by inhibiting CB1 receptor-mediated type 2 NADPH oxidase

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-20825-1_8

The cannabinoid CP55,940 prolongs survival and improves locomotor activity in Drosophila melanogaster against paraquat: implications in Parkinson's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-20825-1_8

An amyloid β42-dependent deficit in anandamide mobilization is associated with cognitive dysfunction in Alzheimer's disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-20825-1_8

The G protein-coupled receptor 55 ligand l-α-lysophosphatidylinositol exerts microglia-dependent neuroprotection after excitotoxic lesion.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-20825-1_8

The therapeutic potential of the endocannabinoid system for Alzheimer's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-20825-1_8

Therapeutic potential of cannabinoid-based drugs.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-20825-1_8

Cannabinoids Delta(9)-tetrahydrocannabinol and cannabidiol differentially inhibit the lipopolysaccharide-activated NF-kappaB and interferon-beta/STAT proinflammatory pathways in BV-2 microglial cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-20825-1_8

Expression of the mRNA coding the cannabinoid receptor 2 in the pallidal complex of Macaca fascicularis

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-20825-1_8

Increased cannabinoid CB1 receptor binding and activation of GTP-binding proteins in the basal ganglia of patients with Parkinson's syndrome and of MPTP-treated marmosets

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-20825-1_8

Loss of mRNA levels, binding and activation of GTP-binding proteins for cannabinoid CB1 receptors in the basal ganglia of a transgenic model of Huntington's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-20825-1_8

Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: relevance to Parkinson's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-20825-1_8

Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-20825-1_8

Type-1 cannabinoid receptor activity during Alzheimer's disease progression.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-20825-1_8

Neuroprotective properties of cannabinoids against oxidative stress: role of the cannabinoid receptor CB1.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-20825-1_8

CB1 cannabinoid receptors and on-demand defense against excitotoxicity

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-20825-1_8

Prolonged oral cannabinoid administration prevents neuroinflammation, lowers β-amyloid levels and improves cognitive performance in Tg APP 2576 mice.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-20825-1_8

Endogenous interleukin-1 receptor antagonist mediates anti-inflammatory and neuroprotective actions of cannabinoids in neurons and glia.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-20825-1_8

Blockade of 45Ca2+ influx through the N-methyl-D-aspartate receptor ion channel by the non-psychoactive cannabinoid HU-211.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-20825-1_8

Endocannabinoid hydrolysis generates brain prostaglandins that promote neuroinflammation

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-20825-1_8

Glial expression of cannabinoid CB(2) receptors and fatty acid amide hydrolase are beta amyloid-linked events in Down's syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-20825-1_8

Oleamide suppresses lipopolysaccharide-induced expression of iNOS and COX-2 through inhibition of NF-kappaB activation in BV2 murine microglial cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-20825-1_8

Endocannabinoid-mediated retrograde modulation of synaptic transmission

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-20825-1_8

Is lipid signaling through cannabinoid 2 receptors part of a protective system?

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-20825-1_8

Microglial CB2 cannabinoid receptors are neuroprotective in Huntington's disease excitotoxicity.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-20825-1_8

An endogenous cannabinoid (2-AG) is neuroprotective after brain injury

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-20825-1_8

Mechanisms of cannabidiol neuroprotection in hypoxic-ischemic newborn pigs: role of 5HT(1A) and CB2 receptors.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-20825-1_8

The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-20825-1_8

Alteration of the endocannabinoid system in mouse brain during prion disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-20825-1_8

The cannabinoid receptor agonist WIN 55,212-2 attenuates the effects induced by quinolinic acid in the rat striatum.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-20825-1_8

A dysregulated endocannabinoid-eicosanoid network supports pathogenesis in a mouse model of Alzheimer's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-20825-1_8

High endogenous cannabinoid levels in the cerebrospinal fluid of untreated Parkinson's disease patients.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-20825-1_8

WIN55,212-2, a cannabinoid receptor agonist, protects against nigrostriatal cell loss in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-20825-1_8

Prevention of Alzheimer's disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-20825-1_8

Changes in CB(1) and CB(2) receptors in the post-mortem cerebellum of humans affected by spinocerebellar ataxias

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-20825-1_8

Endocannabinoid-hydrolysing enzymes in the post-mortem cerebellum of humans affected by hereditary autosomal dominant ataxias

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-20825-1_8

Autosomal dominant cerebellar ataxias: a systematic review of clinical features

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-20825-1_8

Cannabidiol reduces lipopolysaccharide-induced vascular changes and inflammation in the mouse brain: an intravital microscopy study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-20825-1_8

Cannabidiol reduced the striatal atrophy caused 3-nitropropionic acid in vivo by mechanisms independent of the activation of cannabinoid, vanilloid TRPV1 and adenosine A2A receptors.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-20825-1_8

Cannabinoid CB2 receptor agonists protect the striatum against malonate toxicity: relevance for Huntington's disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-20825-1_8

Neuroprotective effects of phytocannabinoid-based medicines in experimental models of Huntington's disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-20825-1_8

Cannabinoids: novel medicines for the treatment of Huntington's disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-20825-1_8

Clinical trials in Huntington's disease: Interventions in early clinical development and newer methodological approaches

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-20825-1_8

COX-2 oxidative metabolite of endocannabinoid 2-AG enhances excitatory glutamatergic synaptic transmission and induces neurotoxicity.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-20825-1_8

Cannabidiol promotes amyloid precursor protein ubiquitination and reduction of beta amyloid expression in SHSY5YAPP+ cells through PPARγ involvement

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-20825-1_8

Cannabinoid receptor agonists protect cultured rat hippocampal neurons from excitotoxicity.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-20825-1_8

WIN55,212-2 inhibits production of CX3CL1 by human astrocytes: involvement of p38 MAP kinase

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-20825-1_8

Dexanabinol (HU-211): A nonpsychotropic cannabinoid with neuroprotective properties

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-20825-1_8

Peroxisome proliferator-activated receptors: "key" regulators of neuroinflammation after traumatic brain injury

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-20825-1_8

Cannabinoid and cannabinoid-like receptors in microglia, astrocytes, and astrocytomas

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-20825-1_8

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-20825-1_8

The activation of cannabinoid CB2 receptors stimulates in situ and in vitro beta-amyloid removal by human macrophages

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-20825-1_8

Sativex-like combination of phytocannabinoids is neuroprotective in malonate-lesioned rats, an inflammatory model of Huntington's disease: role of CB1 and CB2 receptors.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-20825-1_8

The inhibition of 2-arachidonoyl-glycerol (2-AG) biosynthesis, rather than enhancing striatal damage, protects striatal neurons from malonate-induced death: a potential role of cyclooxygenase-2-dependent metabolism of 2-AG.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-20825-1_8

Neuroprotective properties of cannabigerol in Huntington's disease: studies in R6/2 mice and 3-nitropropionate-lesioned mice.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-20825-1_8

Neuroprotection by Delta9-tetrahydrocannabinol, the main active compound in marijuana, against ouabain-induced in vivo excitotoxicity.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-20825-1_8

Endocannabinoids and beta-amyloid-induced neurotoxicity in vivo: effect of pharmacological elevation of endocannabinoid levels.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-20825-1_8

Endocannabinoids regulate the activity of astrocytic hemichannels and the microglial response against an injury: In vivo studies.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-20825-1_8

Functions of the CB1 and CB 2 receptors in neuroprotection at the level of the blood-brain barrier

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-20825-1_8

Nonpsychotropic cannabinoid receptors regulate microglial cell migration.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-20825-1_8

Effects of cannabinoid receptor type 2 on endogenous myocardial regeneration by activating cardiac progenitor cells in mouse infarcted heart.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-20825-1_8

Cannabinoid receptor binding and messenger RNA expression in human brain: an in vitro receptor autoradiography and in situ hybridization histochemistry study of normal aged and Alzheimer's brains

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-20825-1_8

PPARγ/RXRα-induced and CD36-mediated microglial amyloid-β phagocytosis results in cognitive improvement in amyloid precursor protein/presenilin 1 mice.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-20825-1_8

10.1007/978-3-319-20825-1_8

31 March 2020

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26408163%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

1 reference